TORONTO, Jan. 16, 2013 /CNW/ - Lundbeck Canada, a leading provider of medications for treating mental illness, today expressed its strong support for the new national standard on psychological health and safety in the workplace.
"Prevention is always the best way of reducing possible harm," said Patrick Cashman, President of Lundbeck Canada. "Establishing this clear, tangible approach to help Canada's employers better protect the mental health of their team members is an extremely important and positive step forward."
The National Standard of Canada on Psychological Health and Safety in the Workplace is voluntary, however it includes explicit requirements for development of a psychological health and safety management plan, identifying situations or processes which could present risks to psychological health, and ensuring that employees are connected to services or resources to help deal with mental illness.
"Steel-toed boots and other measures to protect the physical health of employees are viewed as a given in Canadian workplaces; it's imperative that mental and psychological health be viewed in an equally important way," said Cashman.
"Better protecting the mental well-being of our country's workforce benefits all Canadians through better productivity, lower health care costs and having healthier, happier people driving our economy."
As a company dedicated to constantly improving the quality of lives of people who live with mental illness, Lundbeck Canada has put measures in place aimed at maintaining and improving the mental well-being of its employees. Flexible work hours, the ability to work from home and an annual $500.00 benefit per employee to direct towards any activity that contributes to psychological or physical well-being (e.g. yoga classes, gym membership, photography classes) are all offered to help Lundbeck Canada employees reduce stress and maintain good mental health through an optimal work-life balance
ABOUT LUNDBECK CANADA
A division of the Denmark-based pharmaceutical maker H. Lundbeck A/S, Lundbeck Canada Inc. has been a trusted source of innovative treatments for Canadians since 1995 with headquarters in Montreal. Originally focused on providing products for the treatment of depression, anxiety, Alzheimer's disease and schizophrenia, Lundbeck Canada now offers cancer therapies for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma. Lundbeck's Celexa® and Cipralex ® are two of the most widely used anti-depressants prescribed by Canadian doctors. A patient-focused partner in Canadian health care, Lundbeck Canada's mission is to improve the quality of life of people suffering from Central Nervous System disorders and cancer.
Globally, Lundbeck was ranked #1 in a 2012 global survey by PatientView that evaluated the ability of pharmaceutical companies to meet patient expectations. In the survey, Lundbeck also took top honours in "best at providing high-quality information to patients" and "best at being transparent with external stakeholders".
SOURCE: Lundbeck Canada Inc
For further information:
Daniel McCarthy, Senior Director, External Relations
Lundbeck Canada Inc.
Phone (514) 501.6381
Ashley Curran, Senior Account Manager